# FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer

> **NCT02317302** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 48 (actual)

## Conditions studied

- Cervical Cancer
- Uterine Cervical Cancer
- Uterine Cervical Neoplasms

## Interventions

- **DEVICE:** FDG-PET/MR
- **DEVICE:** FDG-PET/CT

## Key facts

- **NCT ID:** NCT02317302
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06-28
- **Primary completion:** 2020-06-02
- **Final completion:** 2020-06-02
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Insufficient funding
- **Last updated:** 2020-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02317302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02317302, "FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02317302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*